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We do not believe our analyses adopted a set of singularly
vaccine unfavourable conditions.1 A University of Warwick
team commissioned by the Department of Health to
independently review the modelling and parameters found “no
major defects with the model,” recommending changes that
would have led to vaccination appearing less cost effective than
in our base case.2 We agree with Rappuoli and colleagues and
Black that models and cost effectiveness analyses should be
viewed as tools to aid decision making rather than as “gate
keepers.”3 4 Indeed, in our discussion we stated that, because of
the substantial uncertainty about the model parameters, value
judgments need to be made.1
In using the latest available evidence we included published
data and information from as yet unpublished sources (similarly
to the Novartis model5), submitted in response to the interim
Joint Committee on Vaccination and Immunisation (JCVI)
statement consultation. The case fatality rate in our introduction
(5-10%) relates to laboratory confirmed cases. Our model used
incidence and case fatality from hospital episode statistics data
to also capture clinically diagnosed cases. Although we might
have missed a small number of deaths outside of hospital, the
main reason for the lower case fatality rate we used is the many
more cases we assume in our model compared with laboratory
reports.
In line with National Institute for Health and Care Excellence
(NICE) guidance,6we did not weight quality adjusted life years,
and, although we agree with Glennie and colleagues that
evidence suggests society would favour preference weighting,7
we know of no data that could be used to do this in our models.
The MOSAIC study offers the only matched case controlled
study of disease burden after serogroup Bmeningococcal disease
in England,8 which may partly explain the lower quality of life
loss estimate fromMOSAIC comparedwith those from previous
studies. The fact that the EQ-5D was not designed for children
and may underestimate the health related quality of life loss
from meningococcal disease was recognised by the JCVI when
specifying a quality of life adjustment factor (QAF) of 3 in the
models.
Uncertainty around the model parameters is a key issue when
considering Bexsero vaccination, which we explored using
multiple scenario analyses using discount rates of 3.5% and
1.5%. The models do not include potential technological
advances, although it is difficult to see how as yet unknown
improvements in patient care or available vaccines could be
incorporated.
JCVI and NICE processes to assess cost effectiveness are
analogous in that extra considerations can be included by JCVI
through using adjustment factors and by NICE through
increasing the cost effective threshold.2We considered scenarios
without a QAF applied (table 6). Extending this, considering 2,
4, and +12month vaccination without QAF at various thresholds
the cost effective vaccine price was £3 (€3.8; $4.8), £6, and £12
assuming thresholds of £20 000, £30 000, and up to £50 000,
respectively.
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